Abstract |
Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P<.05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.
|
Authors | Joel T M Bamford, Barbara A Elliott, Irina V Haller |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 50
Issue 1
Pg. 107-8
(Jan 2004)
ISSN: 0190-9622 [Print] United States |
PMID | 14699377
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunosuppressive Agents
- Tacrolimus
|
Topics |
- Female
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Male
- Rosacea
(drug therapy)
- Tacrolimus
(therapeutic use)
|